SCHEMBL2301366

SCHEMBL2301366

FC(F)(F)Oc1ccccc1OC1C[N]C1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
PDE10A Q9Y233 1/20 0.40
SLC6A2 P23975 5/20 0.39
SLC6A3 Q01959 4/20 0.39
HTR1A P08908 3/20 0.39
TRPA1 O75762 1/20 0.38
SCN9A Q15858 3/20 0.38
SLC6A4 P31645 3/20 0.38
EPHX2 P34913 3/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2J2 P51589 2/20 0.37
GRIN2B Q13224 1/20 0.36
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
DDB1 Q16531 2/20 0.34
CRBN Q96SW2 2/20 0.34
HSD11B1 P28845 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2299199 0.83 PDE3B (0.41) PDE3BPDE3APDE10ASLC6A2SLC6A3
SCHEMBL14957027 0.80 SLC6A2 (0.60) SLC6A2SLC6A3HTR1ASLC6A4
SCHEMBL2298452 0.79 SCD (0.49)
SCHEMBL649698 0.76 EPHX2 (0.41) PDE3BPDE3APDE10ASLC6A2SLC6A3
SCHEMBL2301736 0.76 SLC6A2 (0.60) SLC6A2SLC6A3HTR1ASLC6A4
SCHEMBL646216 0.76 EPHX2 (0.41) PDE3BPDE3APDE10ASLC6A2SLC6A3
SCHEMBL2300625 0.76 SLC6A2 (0.50) SLC6A2SLC6A3HTR1ASLC6A4GRIN2B
SCHEMBL4654446 0.76 RXRA (0.47) SLC6A2SLC6A3TRPA1SCN9ASLC6A4
SCHEMBL2300914 0.76 CA1 (0.52) PDE10ASLC6A2SLC6A4EPHX2
Hydrochloric Acid SCHEMBL4100525 0.75 SLC6A2 (0.59) SLC6A2SLC6A3HTR1ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334269-B2 Carboxamides as inhibitors of voltage-gated sodium channels AMGEN INC. (US) 2016-05-10 US disclosed
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2013-05-23 US disclosed
EP-2536689-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN Amgen Inc. (US) 2012-12-26 EP disclosed
WO-2011103196-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN AMGEN INC. (US) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS CACNA1B, SCN1A, CACNA1I PDE3B 894/4885PDE3A 914/4885PDE10A 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.